Pathologically phosphorylated tau protein (Tau (when referring to canonical tau protein; "p-tau" or "phospho-tau" as common abbreviations for phosphorylated tau in pathology))

Pathologically phosphorylated tau protein refers to the tau protein that is aberrantly hyperphosphorylated at multiple residues, resulting in loss of its normal ability to bind and stabilize microtubules and a toxic gain of function in which it aggregates into oligomers and insoluble filaments (paired helical filaments, neurofibrillary tangles), which are the hallmark lesions in tauopathies such as Alzheimer’s disease[1][3][4][6][7]. In its normal state, tau is a microtubule-associated protein that promotes microtubule assembly and axonal stability in neurons[1][4]. Hyperphosphorylation disrupts this function and drives tau dissociation from microtubules, increased aggregation propensity, and neurotoxicity, including impaired axonal transport, synaptic dysfunction, and neuronal death[1][3][4]. Pathologically phosphorylated tau is a validated therapeutic target due to its key role in neurodegenerative disease progression, and is used as a diagnostic biomarker by measuring specific phosphorylated forms in CSF and blood[7]. Therapeutic interventions mainly target abnormal phosphorylation (e.g., kinase inhibitors, immunotherapies) or aggregation pathways; safety and efficacy remain under active clinical investigation.

Other names

Hyperphosphorylated taup-tauphospho-tauabnormal tautau aggregatesAD P-tau (in Alzheimer’s disease)pathological tau

Antibodies: Bind specific pathological p-tau conformers to prevent aggregation, seed propagation, or facilitate clearance[3] Kinase inhibitors: Reduce aberrant phosphorylation of tau O-GlcNAcase inhibitors: Increase O-GlcNAc modification, antagonizing hyperphosphorylation Aggregation inhibitors: Inhibit tau filament formation and oligomerization